Ocumension Therapeutics IPO: Trading Debut
Ocumension Therapeutics (1477 HK) is a China-based ophthalmic pharmaceutical company dedicated to identifying, developing and commercializing...
402 Views
HKEx (388.HK): Trading Volume in May Points to Upside and New License Agreement with MSCI
HKEX (388 HK) just released its May market statistics. The May month ADT (Average Daily Turnover) has registered 14% month-to-month rebound to HKD...
403 Views
Kintor Pharma IPO: Valuation Insights
Kintor Pharmaceutical (9939 HK) is a clinical-stage drug developer with a focus on potential first-in-class and best-in-class drugs for cancers and...
330 Views
Kintor Pharma IPO Initiation: To Screen, or Not to Screen?
Kintor Pharmaceutical (1762178D CH) is a clinical-stage drug developer with a focus on potential first-in-class and best-in-class drugs for cancers...
272 Views
Akesobio: Trading Debut, Valuation Scenario Analysis
Akeso Biopharma Inc (9926 HK) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...
461 Views